Prof. Dr. med. Peter Fasching

Professur für Translationale Frauenheilkunde und Geburtshilfe

Lifestyle and personal factors associated with having macroscopic residual disease after ovarian cancer primary cytoreductive surgery (2023) Phung MT, Webb PM, DeFazio A, Fereday S, Lee AW, Bowtell DD, Fasching P, et al. Journal article Correction: PredictCBC-2.0: a contralateral breast cancer risk prediction model developed and validated in ~ 200,000 patients (Breast Cancer Research, (2022), 24, 1, (69), 10.1186/s13058-022-01567-3) (2022) Giardiello D, Hooning MJ, Hauptmann M, Keeman R, Heemskerk-Gerritsen BA, Becher H, Blomqvist C, et al. Journal article, Erratum Q-TWiST analysis of pembrolizumab combined with chemotherapy as first-line treatment of metastatic triple-negative breast cancer that expresses PD-L1 (2022) Huang M, O'Shaughnessy J, Haiderali A, Pan W, Hu P, Chaudhuri M, Le Bailly De Tilleghem C, et al. Journal article A multicentre, randomised, double-blind, phase II study to evaluate the tolerability of an induction dose escalation of everolimus in patients with metastatic breast cancer (DESIREE) (2022) Schmidt M, Lübbe K, Decker T, Thill M, Bauer L, Müller V, Link T, et al. Journal article PredictCBC-2.0: a contralateral breast cancer risk prediction model developed and validated in ~ 200,000 patients (2022) Giardiello D, Hooning MJ, Hauptmann M, Keeman R, Heemskerk-Gerritsen BAM, Becher H, Blomqvist C, et al. Journal article EVI1 expression in early-stage breast cancer patients treated with neoadjuvant chemotherapy (2022) Leichsenring J, Vladimirova V, Solbach C, Karn T, Ataseven B, Sinn BV, Barinoff J, et al. Journal article Sex-specific association between prenatal androgenization (second-to-fourth digit length ratio) and frontal brain volumes in adolescents (2022) Lenz B, Gerhardt S, Boroumand-Jazi R, Eichler A, Buchholz VN, Fasching P, Kornhuber J, et al. Journal article Machine Learning-based Detection of In-Utero Fetal Presentation from Non-Invasive Fetal ECG (2022) Jäger K, Nissen M, Richer R, Rahm S, Titzmann A, Fasching P, Eskofier B, Leutheuser H Conference contribution, Conference Contribution Matching adjusted indirect comparison of PFS & OS comparing ribociclib plus letrozole vs palbociclib plus letrozole as first-line treatment of HR+/HER2-ABC: Analysis based on updated PFS & final OS results of MONALEESA-2 & PALOMA-2 (2022) Jhaveri K, O'Shaughnessy J, Fasching P, Cardoso F, Tolaney S, Hamilton E, Sharma VK, et al. Conference contribution Safety interim analysis (SIA) of the phase III postneoadjuvant SASCIA study evaluating sacituzumab govitecan (SG) in patients (pts) with primary HER2-negative breast cancer (BC) at high relapse risk after neoadjuvant chemotherapy (NACT) (2022) Marme F, Hanusch C, Furlanetto J, Morris P, Link T, Denkert C, Fasching P, et al. Conference contribution